Acetylation polymorphism expression in patients before and after liver transplantation: influence of host/graft genotypes

被引:9
作者
Bendriss, EK
Bechtel, YC
Paintaud, G
Brientini, MP
Mantion, G
Miguet, JP
Bennani, A
Bechtel, PR [1 ]
机构
[1] CHU Besancon, Serv Pharmacol Clin, F-25030 Besancon, France
[2] Univ Moulay Ismail, Dept Biol, Fac Sci, Meknes, Morocco
[3] CHU Besancon, Serv Hepatol, F-25030 Besancon, France
[4] CHU Besancon, Serv Chirurg Digest & Vasc, F-25030 Besancon, France
来源
PHARMACOGENETICS | 1998年 / 8卷 / 03期
关键词
acetylator; chimerism; genotype; liver transplantation; phenotype;
D O I
10.1097/00008571-199806000-00003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The consequences of liver transplantation on NAT2 activity were studied in 58 patients of Caucasian origin and compared with a group control of 119 unrelated healthy individuals of the same ethnic origin, Acetylation phenotypes were determined using caffeine as a probe drug before and repeatedly after liver transplantation. NAT2 genotypes were determined with three separate polymerase chain reactions to detect either the NAT2*4 wild-type allele or the NAT2*5A, NAT2*6A and NAT2*7A mutated alleles, associated with a decrease in NAT2 enzyme activity, In patients, the molar urinary elimination ratio AFMU/(AFMU + 1X + 1U) appeared more reliable than AFMU/1X for assessing the acetylation. phenotype and fitted better with the various haplotypes. The variation of xanthine oxidase activity as measured by the 1U/1X urinary elimination ratio, appeared to be responsible for the poor phenotype prediction from the AFMU/1X ratio in post-transplanted patients, Regardless of the pathologic conditions or the treatment in progress, the genotype of the liver played an overwhelming role in the phenotypic expression of NAT2 compared with the genotype of other organs, where NAT2 was expressed in patients who presented a chimerism after liver transplantation. Pharmacogenetics 8: 201-209 (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 33 条
[1]  
Ausubel FA, 1995, CURRENT PROTOCOLS MO
[2]  
BECHTEL PR, 1995, ADV DRUG METABOLISM, P137
[3]  
BECHTEL YC, 1993, CLIN PHARMACOL THER, V54, P131
[4]   GENOTYPE-PHENOTYPE DISCORDANCE FOR HUMAN ARYLAMINE N-ACETYLTRANSFERASE (NAT2) REVEALS A NEW SLOW-ACETYLATOR ALLELE COMMON IN AFRICAN-AMERICANS [J].
BELL, DA ;
TAYLOR, JA ;
BUTLER, MA ;
STEPHENS, EA ;
WIEST, J ;
BRUBAKER, LH ;
KADLUBAR, FF ;
LUCIER, GW .
CARCINOGENESIS, 1993, 14 (08) :1689-1692
[5]   STABILITY OF DEBRISOQUINE (CYP2D6) PHENOTYPE IN LIVER-TRANSPLANT PATIENTS [J].
BENDRISS, A ;
BECHTEL, Y ;
PAINTAUD, G ;
BENDRISS, EK ;
JOANNE, C ;
BRESSONHADNI, S ;
MAGNETTE, J ;
BECKER, MC ;
GILLET, M ;
MANTION, G ;
MIGUET, JP ;
BECHTEL, PR .
THERAPEUTIC DRUG MONITORING, 1995, 17 (02) :113-119
[6]   HUMAN ARYLAMINE N-ACETYLTRANSFERASE GENES - ISOLATION, CHROMOSOMAL LOCALIZATION, AND FUNCTIONAL EXPRESSION [J].
BLUM, M ;
GRANT, DM ;
MCBRIDE, W ;
HEIM, M ;
MEYER, UA .
DNA AND CELL BIOLOGY, 1990, 9 (03) :193-203
[7]  
CASCORBI I, 1995, AM J HUM GENET, V57, P581
[8]   ACETYLATOR PHENOTYPING - THE URINARY CAFFEINE METABOLITE RATIO IN SLOW ACETYLATORS CORRELATES WITH A MARKER OF SYSTEMIC NAT1 ACTIVITY [J].
CRIBB, AE ;
ISBRUCKER, R ;
LEVATTE, T ;
TSUI, B ;
GILLESPIE, CT ;
RENTON, KW .
PHARMACOGENETICS, 1994, 4 (03) :166-170
[9]  
EVANS DAP, 1989, PHARMACOL THERAPEUT, V42, P157
[10]   GENETIC CONTROL OF ISONIAZID METABOLISM IN MAN [J].
EVANS, DAP ;
MANLEY, KA ;
MCKUSICK, VA .
BRITISH MEDICAL JOURNAL, 1960, 2 (AUG13) :485-491